Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data

ABSTRACT: Polatuzumab vedotin is an anti-CD79b antibody conjugated to monomethyl auristatin E that has shown significant clinical activity in follicular and diffuse large B-cell lymphoma (DLBCL) and is currently FDA-approved in combination with bendamustine and rituximab for patients with relapsed/r...

Descripción completa

Detalles Bibliográficos
Autores principales: Sawalha, Yazeed, Maddocks, Kami
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293382/
https://www.ncbi.nlm.nih.gov/pubmed/32606733
http://dx.doi.org/10.2147/OTT.S219449
_version_ 1783546291701153792
author Sawalha, Yazeed
Maddocks, Kami
author_facet Sawalha, Yazeed
Maddocks, Kami
author_sort Sawalha, Yazeed
collection PubMed
description ABSTRACT: Polatuzumab vedotin is an anti-CD79b antibody conjugated to monomethyl auristatin E that has shown significant clinical activity in follicular and diffuse large B-cell lymphoma (DLBCL) and is currently FDA-approved in combination with bendamustine and rituximab for patients with relapsed/refractory DLBCL. This review article summarizes data from clinical trials of polatuzumab and discusses its current role and future directions in the treatment of patients with B-cell non-Hodgkin lymphoma. METHODS: We conducted a literature search in PubMed and Google Scholar from inception to January 2020, using the following terms: polatuzumab and CD79. We also reviewed the package insert and available abstracts and posters presented at national and international meetings.
format Online
Article
Text
id pubmed-7293382
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-72933822020-06-29 Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data Sawalha, Yazeed Maddocks, Kami Onco Targets Ther Review ABSTRACT: Polatuzumab vedotin is an anti-CD79b antibody conjugated to monomethyl auristatin E that has shown significant clinical activity in follicular and diffuse large B-cell lymphoma (DLBCL) and is currently FDA-approved in combination with bendamustine and rituximab for patients with relapsed/refractory DLBCL. This review article summarizes data from clinical trials of polatuzumab and discusses its current role and future directions in the treatment of patients with B-cell non-Hodgkin lymphoma. METHODS: We conducted a literature search in PubMed and Google Scholar from inception to January 2020, using the following terms: polatuzumab and CD79. We also reviewed the package insert and available abstracts and posters presented at national and international meetings. Dove 2020-06-08 /pmc/articles/PMC7293382/ /pubmed/32606733 http://dx.doi.org/10.2147/OTT.S219449 Text en © 2020 Sawalha and Maddocks. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Sawalha, Yazeed
Maddocks, Kami
Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data
title Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data
title_full Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data
title_fullStr Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data
title_full_unstemmed Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data
title_short Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data
title_sort profile of polatuzumab vedotin in the treatment of patients with relapsed/refractory non-hodgkin lymphoma: a brief report on the emerging clinical data
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293382/
https://www.ncbi.nlm.nih.gov/pubmed/32606733
http://dx.doi.org/10.2147/OTT.S219449
work_keys_str_mv AT sawalhayazeed profileofpolatuzumabvedotininthetreatmentofpatientswithrelapsedrefractorynonhodgkinlymphomaabriefreportontheemergingclinicaldata
AT maddockskami profileofpolatuzumabvedotininthetreatmentofpatientswithrelapsedrefractorynonhodgkinlymphomaabriefreportontheemergingclinicaldata

Ejemplares similares